Boulder, Colorado · reference desk
A calm starting point for Boulder readers sorting through ibogaine policy, research pathways, safety questions, and the difference between changing state rules and federal law.
This page is designed for practical orientation: what Colorado permits, where federal rules still matter, and how to check claims against primary materials. For the broader Boulder-area framing, begin with the site’s plain-language overview of ibogaine in Colorado.
Colorado’s policy landscape is not the same thing as federal scheduling. The U.S. Drug Enforcement Administration lists controlled substances through its federal drug scheduling information, while state law and local implementation can create a separate set of questions about possession, cultivation, services, and regulated access.
Treat a change in state policy as a reason to verify the details—not as a blanket answer about legality, availability, or safety.
For questions about Colorado’s natural medicine framework, the most durable reference point is the statutory text and the agencies responsible for implementation. The Colorado General Assembly’s SB23-290 record is a useful entry point for checking the law and its legislative history.
Terminology matters. A general definition of ibogaine can help distinguish the substance from broader labels, but it does not answer a legal or medical question for an individual situation. The site’s Colorado legal overview is structured to help readers separate those layers before relying on any interpretation.
When a source describes a pilot, a facilitator, a service center, or a research study, check which authority governs it and whether the language is describing a proposal, a current rule, or an independently run activity.
Colorado’s natural medicine framework and federal law are separate. Ibogaine remains federally controlled, and legal implications can turn on the conduct, setting, and applicable jurisdiction. Check current statutory language rather than relying on a headline or a secondhand summary.
This independent resource does not identify or endorse providers. State policy developments should not be treated as a guarantee that a specific service is legal, available, regulated, or appropriate. The Boulder treatment-pathway guide explains the distinctions worth checking.
Research studies typically use defined protocols, eligibility criteria, consent processes, and oversight. The U.S. National Library of Medicine maintains ClinicalTrials.gov, a public registry that can be used to look for study listings and their stated status.
Health and safety questions deserve qualified professional input. In a research setting, a protocol sets reporting expectations; outside research, urgent concerns should be directed to emergency services or an appropriate health professional. Federal health information also notes that psychedelics and dissociative drugs can involve risks and active areas of research.
Start with the law or agency page, then compare it with federal scheduling and study records. If you are evaluating information found online, keep a clear distinction between policy, research, personal experience, and health guidance. The broader resource safe ibogaine therapy guidance may help readers frame questions around safety and claims, but it does not replace legal or medical advice.
For questions about how this site approaches uncertainty and source review, the mission and information principles describe the standard behind these materials. If a question is not addressed here, use the available contact route for the resource rather than assuming that silence signals permission or endorsement.